ST. PAUL, Minn.--(BUSINESS WIRE)--St. Jude Medical, Inc. (NYSE:STJ) today announced regulatory approval from the Ministry of Health, Labor and Welfare (MHLW), in addition to reimbursement approval, for the Company’s first CRT-D systems in Japan to treat heart failure patients. Two new systems used to treat heart failure patients have been approved, including the Atlas®+ HF CRT-D (cardiac resynchronization therapy defibrillator) and the Epic® HF CRT-D that are used in conjunction with the QuickSite® left-heart lead and delivered through the Apeel® CS catheter delivery system.
